Taysha Gene Therapies (NASDAQ:TSHA) Earns Market Outperform Rating from JMP Securities

JMP Securities restated their market outperform rating on shares of Taysha Gene Therapies (NASDAQ:TSHA) in a research report sent to investors on Tuesday,Benzinga reports. JMP Securities currently has a $5.00 price objective on the stock.

A number of other equities analysts have also weighed in on the company. Chardan Capital restated a “buy” rating and issued a $7.00 target price on shares of Taysha Gene Therapies in a research note on Tuesday, August 13th. Cantor Fitzgerald restated an “overweight” rating and issued a $7.00 price objective on shares of Taysha Gene Therapies in a research report on Tuesday. Canaccord Genuity Group dropped their target price on shares of Taysha Gene Therapies from $7.00 to $6.00 and set a “buy” rating for the company in a research report on Wednesday, August 14th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $6.00 price target on shares of Taysha Gene Therapies in a research note on Tuesday. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Taysha Gene Therapies presently has a consensus rating of “Buy” and an average price target of $6.38.

Taysha Gene Therapies Price Performance

TSHA stock opened at $2.39 on Tuesday. The firm has a 50 day moving average of $1.97 and a 200-day moving average of $2.39. The firm has a market capitalization of $489.81 million, a P/E ratio of -10.40 and a beta of 0.44. Taysha Gene Therapies has a 12 month low of $1.19 and a 12 month high of $4.32. The company has a current ratio of 5.22, a quick ratio of 5.22 and a debt-to-equity ratio of 0.35.

Taysha Gene Therapies (NASDAQ:TSHA) last released its quarterly earnings results on Monday, August 12th. The company reported ($0.09) EPS for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.01. Taysha Gene Therapies had a negative net margin of 888.18% and a negative return on equity of 168.91%. The firm had revenue of $1.11 million during the quarter, compared to analyst estimates of $3.62 million. During the same period in the previous year, the business earned ($0.38) EPS. As a group, sell-side analysts predict that Taysha Gene Therapies will post -0.35 earnings per share for the current fiscal year.

Institutional Trading of Taysha Gene Therapies

Several hedge funds and other institutional investors have recently bought and sold shares of TSHA. Creative Planning purchased a new position in shares of Taysha Gene Therapies during the third quarter worth approximately $28,000. Principal Financial Group Inc. bought a new position in shares of Taysha Gene Therapies during the 2nd quarter valued at $48,000. China Universal Asset Management Co. Ltd. raised its position in Taysha Gene Therapies by 79.4% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 39,417 shares of the company’s stock worth $79,000 after purchasing an additional 17,446 shares during the period. Intech Investment Management LLC bought a new stake in Taysha Gene Therapies in the third quarter worth $85,000. Finally, Scientech Research LLC bought a new stake in Taysha Gene Therapies in the second quarter worth $97,000. Hedge funds and other institutional investors own 77.70% of the company’s stock.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.